ZymoGenetics will use Dyax’ antibody phage display libraries to discover therapeutic antibodies according to a nonexclusive license.
ZymoGenetics also received sublicenses to relevant third-party antibody phage display patents that may be used with Dyax’ antibody phage display technology. Under the terms of the agreement, Dyax will receive upfront and annual technology license fees, clinical milestone payments, and royalties on net sales of products that may result from this transaction.